FY2025 EPS Forecast for Astria Therapeutics Cut by Analyst

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Research analysts at Wedbush lowered their FY2025 earnings per share estimates for Astria Therapeutics in a note issued to investors on Wednesday, November 12th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of ($2.24) per share for the year, down from their previous estimate of ($1.97). Wedbush currently has a “Neutral” rating and a $13.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. Wedbush also issued estimates for Astria Therapeutics’ Q4 2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.00) EPS.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The company had revenue of $0.71 million during the quarter, compared to analyst estimates of $10.67 million.

A number of other equities analysts have also commented on the stock. Lifesci Capital lowered shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Jefferies Financial Group downgraded shares of Astria Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $30.00 to $13.00 in a report on Tuesday, October 14th. HC Wainwright lowered shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Evercore ISI reaffirmed an “outperform” rating and issued a $26.00 price target on shares of Astria Therapeutics in a report on Wednesday, October 1st. Finally, Cantor Fitzgerald lowered Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Wednesday, November 12th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $24.50.

Astria Therapeutics Stock Down 0.6%

ATXS stock opened at $12.49 on Monday. The stock has a 50-day simple moving average of $10.08 and a two-hundred day simple moving average of $7.33. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.72. The firm has a market capitalization of $712.99 million, a PE ratio of -6.21 and a beta of 0.21.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in shares of Astria Therapeutics by 10,311.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 3,506 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Astria Therapeutics by 185.8% in the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,557 shares in the last quarter. Brooklyn Investment Group boosted its stake in Astria Therapeutics by 1,079.6% in the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock worth $46,000 after buying an additional 7,957 shares in the last quarter. Brevan Howard Capital Management LP bought a new position in Astria Therapeutics during the third quarter valued at approximately $98,000. Finally, Corton Capital Inc. purchased a new position in shares of Astria Therapeutics during the first quarter worth approximately $72,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.